NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes

 NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics
                                 for Diabetes

PR Newswire

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- NGM
Biopharmaceuticals, Inc. announced today that it has signed a worldwide
agreement with Janssen Pharmaceuticals, Inc. to discover and develop novel
therapeutics for the potential treatment of Type 2 diabetes and other
metabolic diseases. 

NGM and Janssen will jointly conduct research on selected protein factors
discovered by NGM using its diabetes discovery platform, with the goal of
advancing drug candidates that mimic the potential glucoregulatory effects of
bariatric surgery on diabetes patients. Janssen will receive an exclusive
worldwide license to develop, manufacture and commercialize compounds
resulting from the collaboration.

Under the terms of the agreement, NGM will receive an upfront payment and
research support for activities conducted in collaboration with Janssen. In
addition, NGM is eligible to receive payments upon the achievement of certain
research, development, regulatory and commercial milestones, as well as
royalties on worldwide product sales. 

"NGM's commitment to drug discovery has resulted in a deep pipeline of novel
targets that have a potentially profound effect on metabolic diseases," said
Jin-Long Chen, Ph.D., founder, president and chief scientific officer of NGM.
"We are pleased to be working with Janssen, who will bring world-class drug
discovery and development expertise to the advancement of NGM's first-in-class
therapies for the treatment of patients with diabetes."

About NGM Biopharmaceuticals, Inc.

Founded in 2008, NGM is a privately-held drug discovery company in South San
Francisco, California committed to the identification and development of
transformational biologics for diabetes, obesity and other cardio-metabolic
diseases. The Company is focused on discovering the next generation of
therapeutics that will fundamentally change the treatment paradigm for the
growing population of diabetes and obesity patients worldwide. NGM has
established collaborations with Daiichi Sankyo in the area of beta cell
regeneration, and with JDRF to discover novel biologics for the treatment of
Type 1 diabetes. For more information, please visit the company's website at

SOURCE NGM Biopharmaceuticals, Inc.

Contact: NGM Biopharmaceuticals, Inc., Aetna Wun Trombley, Ph.D.,
Press spacebar to pause and continue. Press esc to stop.